Cambrex, a CDMO, signed an agreement with Eli Lilly to deliver accelerated access to clinical development capabilities for Lilly’s biotech collaborators. The company will partner with Lilly Catalyze360-ExploR&D, Lilly’s early external innovation and collaboration arm, to provide drug substance, drug product, analytical service labs and R&D expertise to Lilly Catalyze360 biotech collaborators.
“We are excited to support Lilly’s mission to enable external biotech collaborators to expedite their product development,” said Brandon Fincher, president of early stage development and testing at Cambrex. “Our Longmont facility offers all services required to advance early stage small molecules into the clinic with speed, flexibility, and scientific excellence. We look forward to propelling Lilly Cataylze360 collaborators forward on an efficient path to success with their products.”
Lilly Catalyze360 invests in advancing science and supporting emerging medicines through its three pillars: Lilly Ventures, Lilly Gateway Labs, and Lilly ExploR&D. For this strategic agreement, Cambrex will partner with…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
